 |
|
Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?
Yun Bin Lee, Jeong-Hoon Lee
Clin Mol Hepatol. 2017;23(3):219-221. Published online 2017 Sep 19 DOI: https://doi.org/10.3350/cmh.2017.0045
|
|
Citations to this article as recorded by
 Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms
Jolynne Mokaya, Anna L. McNaughton, Phillip A Bester, Dominique Goedhals, Eleanor Barnes, Brian D Marsden, Philippa C. Matthews
Wellcome Open Research.2020; 5: 151. CrossRef Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
Hyun Young Woo, Jun Yong Park, Si Hyun Bae, Chang Wook Kim, Jae Young Jang, Won Young Tak, Dong Joon Kim, In Hee Kim, Jeong Heo, Sang Hoon Ahn
Clinical and Molecular Hepatology.2020; 26(3): 352. CrossRef
|